FDA approves Quartette (Teva) for Contraception.
Teva Pharmaceutical Industries Ltd. announced that the FDA has on 28 March 2013, approved Quartette, (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for prevention of pregnancy.
The Phase III clinical trial, which involved more than 3,000 women, found that Quartette was 97 percent effective at preventing pregnancy. According to Teva, Quartette represents the next generation of extended regimen oral contraceptives to be approved by the FDA.The product was designed to minimize breakthrough bleeding between scheduled periods.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins